Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

Supporting evidence

• Evaluation report

• Draft guidance consultation committee papers (PDF 8.66 MB)

  Published:

  10 May 2023

• Final draft guidance committee papers (PDF 948 KB)

  Published:

  10 May 2023